1-amino-9H-xanthen-9-one | 54829-44-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 1-amino-9H-xanthen-9-one
• 英文别名: 1-aminoxanthone；1-amino-xanthen-9-one；1-Amino-xanthen-9-on；aminoxanthone；1-aminoxanthen-9-one
• CAS: 54829-44-6
• 化学式: C₁₃H₉NO₂
• 分子量: 211.22
• InChiKey: TYVCGEVIYKZPEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-amino-9H-xanthen-9-one 生成 1-chloro-9H-xanthen-9-one
  参考文献：
  名称：

  859.黄嘌呤：3'-取代的2-羧基二苯醚的环化

  摘要：

  DOI：

  10.1039/jr9580004227
• 作为产物：
  描述：

  占吨酮 在 silver hexafluoroantimonate 、 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 、 硫酸 、 cesium acetate 作用下， 以 水 、 1,2-二氯乙烷 为溶剂， 反应 15.33h， 生成 1-amino-9H-xanthen-9-one
  参考文献：
  名称：

  Ru（II）催化磺酰叠氮化物对ant吨酮和色酮的选择性C–H胺合成：合成和抗癌性评估

  摘要：

  描述了酮辅助钌催化的x吨酮和色酮CH键与磺酰叠氮化物的选择性胺化反应。反应可在具有优异官能团相容性的多种底物上高效进行。该协议可直接访问已知具有有效抗癌活性的1-氨基黄嘌呤，5-氨基色酮和5-氨基类黄酮衍生物。

  DOI：

  10.1021/jo501709f

文献信息

• Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof
  申请人：Petasis Nicos A.

  公开号：US20090247766A1

  公开（公告）日：2009-10-01

  The invention relates to a nitrogen heterocycle compound of formula 1: Also disclosed are a method of synthesizing the compound and use of the compound for treating various diseases and conditions.

  该发明涉及一种化学式为1的氮杂环化合物。还公开了一种合成该化合物的方法，以及利用该化合物治疗各种疾病和病况的用途。
• Tetrazolyl substituted tricyclic compounds and pharmacological
  申请人：Burroughs Welcome Co.

  公开号：US04902701A1

  公开（公告）日：1990-02-20

  Tricyclic compounds of formula (I) ##STR1## wherein X.sup.1 is a carboxyl or 5-tetrazolyl group X.sup.2 is carbonyl or methylene X.sup.3 is hydroxyl or a group --X.sup.4 (C.sub.n H.sub.2n)X.sup.5 where X.sup.4 is oxygen or sulphur X.sup.5 is hydrogen or a group --OX.sup.6 where X.sup.6 is hydrogen, alkanoyl of 1 to 4 carbon atoms or a group --(C.sub.m H.sub.2m)X.sup.7 where X.sup.7 is hydrogen or a group --OX.sup.8 where X.sup.8 is hydrogen or alkanoyl of 1 to 4 carbon atoms and m and n are each, independently, an integer from 1 to 4, together with salts thereof, provided that when X.sup.5 is a group --OX.sup.6 then n is always greater than 1 and X.sup.4 and X.sup.5 are attached to different carbon atoms and that when X.sup.7 is a group --OX.sup.8 then m is always greater than 1 and no single carbon atom in the radical --(C.sub.m H.sub.2m)-- is attached to two oxygen atoms. These compounds are of value in medicine in circumstances where it is desirable to provide a more effective delivery of oxygen to the tissues; in vivo applications include the relief or amelioration of tissue hypoxia as in, for example, cardiac or cerebral ischaemia while in vitro they maintain the oxygen-delivery capacity of stored red blood cells and prolong the cells' useful storage life. The invention is also directed to methods for the preparation of the compounds, to pharmaceutical formulations and other presentation forms containing them and the preparation thereof, to the use of the compound in medicine, and to novel intermediates for the said compounds and the preparation thereof.

  式（I）的三环化合物##STR1##其中X.sup.1是羧基或5-四唑基团，X.sup.2是酰基或亚甲基，X.sup.3是羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟基或羟
• Synthesis of [1]Benzopyrano[2,3,4-kl]acridin-3-ol and Its Analogues as Pentacyclic Compounds.
  作者：Hidetoshi FUJIWARA、Kouki KITAGAWA

  DOI：10.1248/cpb.48.1380

  日期：——

  A new heterocyclic compound, [1]benzopyrano[2, 3, 4-kl]acridin-3-ol was synthesized by cyclization of xanthone derivatives. The key compound, 1-(3'-methoxyanilino)-xanthone, was prepared from 1-aminoxanthone. [1]benzopyrano[2, 3, 4-kl]acridin-3-ol analogues, [1]benzothiopyrano[2, 3, 4-kl]acridin-3-ol, pyrido[3', 2' : 5, 6]pyrano[2, 3, 4-kl]acridin-3-ol and pyrido[3', 2' : 5, 6]thiopyrano[2, 3, 4-kl]acridin-3-ol were synthesized by the same method.

  通过氧杂蒽酮衍生物的环化合成了一种新的杂环化合物[1]苯并吡喃并[2,3,4-kl]吖啶-3-醇。关键化合物 1-(3'-甲氧基苯胺基)-呫吨酮是由 1-氨基呫吨酮制备的。 [1]苯并吡喃并[2, 3, 4-kl]吖啶-3-醇类似物、[1]苯并噻喃并[2, 3, 4-kl]吖啶-3-醇、吡啶并[3', 2' : 5, 6用同样的方法合成了]吡喃并[2, 3, 4-kl]吖啶-3-醇和吡啶并[3', 2' : 5, 6]噻喃并[2, 3, 4-kl]吖啶-3-醇。
• Initiator system for radiation curable compositions, radiation curable compositions containing such an initiator system, a process for curing said compositions and products covered therewith
  申请人：AKZO N.V.

  公开号：EP0037604A1

  公开（公告）日：1981-10-14

  In the initiator system are incorporated: a) a photoinitiator, with the exception of a compound of theformula: wherein R, = H or an alkyl group, an alkenyl group, a cycloalkyl or cycloalkenyl group, an aryl group, a furfuryl group orthe group where Y represents a methyl group and Z an alkyl group or Y and Z together form a 1,3- or 1,4-alkylene group having 3 or carbon atoms; R2 = an alkyl group or alkenyl group, a cycloalkyl group or cycloalkenyl group, an alkaryl group or a furfuryl group; R3 and R4 may be the same or different and represent a hydrogen, a chlorine or a bromine atom or a phenyl group, an alkyl group or alkoxy group, or a dialkyl amino group; b) a synergistic amount of a Na, K and/or Li-salt of an organic acid having at least 4 carbon atoms which is compatible with the curable compositions, and c) a solvent for component b in such an amount that the solution of salt b in the curable compositions is just about saturated or nearly saturated. The initiator system cures rapidly and has good storage stability.

  在启动器系统中加入了 a) 光引发剂，但以下式子的化合物除外： 其中 R, = H 或烷基、烯基、环烷基或环烯基、芳基、糠基或基团 其中 Y 代表甲基，Z 代表烷基，或 Y 和 Z 共同形成具有 3 个或更多碳原子的 1,3- 或 1,4- 烯基；R2 = 烷基或烯基、环烷基或环烯基、芳基或糠基；R3 和 R4 可以相同或不同，代表氢、氯原子或溴原子或苯基、烷基或烷氧基或二烷基氨基； b) 与可固化组合物相容的具有至少 4 个碳原子的有机酸的 Na、K 和/或 Li 盐的协同量，以及 c) 成分 b 的溶剂，其用量应使盐 b 在可固化组合物中的溶液接近饱和或接近饱和。 引发剂体系固化速度快，储存稳定性好。
• Tricyclic compounds, preparation, use and intermediates
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0093381A1

  公开（公告）日：1983-11-09

  Tricyclic compounds of formula (I) wherein X' is a carboxyl or 5-tetrazolyl group X2 is carbonyl or methylene X3 is hydroxyl or a group -X4(CnH2n)X5 where X4 is oxygen or sulphur X6 is hydrogen or a group -OX6 where X6 is hydrogen, alkanoyl of 1 to 4 carbon atoms or a group -(CmH2m)X7 where X7 is hydrogen or a group -OX8 where X8 is hydrogen or alkanoyl of 1 to 4 carbon atoms and m and n are each, independently, an integer from 1 to 4, together with salts thereof, provided that when X5 is a group -OX6 then n is always greater than 1 and X4 and X5 are attached to different carbon atoms and that when X7 is a group -OX8 then m is always greater than 1 and no single carbon atom in the radical -(CmH2m)-is attached to two oxygen atoms. These compounds are of value in medicine in circumstances where it is desirable to provide a more effective delivery of oxygen to the tissues; in vivo applications include the relief or amelioration of tissue hypoxia as in, for example, cardiac or cerebral ischaemia while in vitro they maintain the oxygen-delivery capacity of stored red blood cells and prolong the cells' useful storage life. The invention is also directed to methods for the preparation of the compounds, to pharmaceutical formulations and other presentation forms containing them and the preparation thereof, to the use of the compounds in medicine, and to novel intermediates for the said compounds and the preparation thereof.

  式 (I) 的三环化合物 其中 X' 是羧基或 5-四唑基 X2 是羰基或亚甲基 X3 是羟基或基团 -X4(CnH2n)X5 其中 X4 是氧或硫 X6 是氢或基团 -OX6 其中 X6 是氢、1 至 4 个碳原子的烷酰基或基团-(CmH2m)X7 其中 X7 是氢或基团 -OX8 其中 X8 是氢或 1 至 4 个碳原子的烷酰基，m 和 n 各自独立地为 1 至 4 的整数，以及它们的盐、 条件是当 X5 为基团-OX6 时，n 始终大于 1，且 X4 和 X5 连接在不同的碳原子上 当 X7 为基团-OX8 时，m 始终大于 1，且自由基-(CmH2m)-中没有单个碳原子与两个氧原子相连。 这些化合物在医学上的应用价值在于，可以更有效地向组织输送氧气；在体内的应用包括缓解或改善组织缺氧，如心肌或脑缺血，而在体外的应用则是保持储存的红细胞的氧气输送能力，延长细胞的有效储存寿命。 本发明还涉及这些化合物的制备方法、含有这些化合物的药物制剂和其他呈现形式及其制备方法、这些化合物在医学中的用途，以及上述化合物的新型中间体及其制备方法。